New hope for lung cancer patients whose treatment stopped working
NCT ID NCT03758287
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs (ningetinib and gefitinib) in 108 people with advanced non-small cell lung cancer whose tumors had a specific gene change (EGFR mutation) but not another (T790M), and whose cancer had stopped responding to standard targeted therapy. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. This is not a cure, but aims to control the cancer for a longer time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.